🪖 Military Warns Troops That Federal Marijuana Rescheduling Does Not Permit Cannabis Use

The Department of War has issued new guidance reminding military service members and civilian employees that marijuana use, possession, distribution and manufacture remain prohibited despite the Trump administration’s ongoing federal cannabis rescheduling efforts. The memo states that violations remain punishable under the Uniform Code of Military Justice and emphasizes that state legalization, including medical marijuana programs, does not change military policy or create protections for active-duty personnel. While certain medical cannabis products have already been moved to Schedule III at the federal level, military officials stress that the armed forces will continue maintaining a drug-free workplace, underscoring the gap between broader cannabis reforms and rules governing military service. (Marijuana Moment)

🧠 Cannabis-Derived Treatment Significantly Reduces Agitation in Late-Stage Dementia Patients

A first-of-its-kind Phase II clinical trial found that a medical formulation containing THC and CBD significantly reduced agitation in hospice-eligible patients with Alzheimer’s disease and other forms of dementia, outperforming a placebo in a randomized, double-blind study. The LiBBY trial enrolled 120 participants across 10 U.S. medical centers, with nearly 90% of treated patients showing overall improvement after 12 weeks and many experiencing measurable benefits within just two weeks. Researchers say the findings are especially significant because current treatments for dementia-related agitation often have limited effectiveness and substantial side effects, suggesting cannabis-derived therapies could offer a promising new option for improving quality of life in late-stage dementia care. (Medical Xpress)

🌎 Senate Democrats Introduce Bill to Fully Legalize Marijuana Nationwide

A group of Senate Democrats led by Cory Booker, Chuck Schumer and Ron Wyden has reintroduced the Cannabis Administration and Opportunity Act (CAOA), a sweeping proposal that would completely remove marijuana from the federal Controlled Substances Act rather than simply move it to Schedule III. The legislation would establish a federal regulatory framework, create pathways for expunging certain cannabis convictions, restore rights and opportunities lost due to past marijuana offenses, and invest tax revenue into communities disproportionately impacted by prohibition. The bill goes significantly further than the Trump administration’s current rescheduling effort and would also prevent the planned federal crackdown on hemp-derived THC products, though similar versions introduced in prior congressional sessions have not advanced to enactment.

👉 Read The Full Study Here

📚 Researchers Say Better Cannabis Education Could Reduce Demand for High‑Potency THC Products

Canadian researchers are calling for stronger public education about cannabis compounds, arguing that many consumers mistakenly equate higher THC levels with higher quality, leading them to seek out increasingly potent products that may carry greater health risks. Health experts note that long‑term use of high‑THC cannabis has been associated with increased risks of anxiety, depression and other adverse effects, while emphasizing that THC percentage alone does not determine a product’s overall effects. The article highlights growing interest in educating consumers about the broader range of cannabinoids and terpenes found in cannabis, with researchers suggesting that better understanding of these compounds could encourage more informed purchasing decisions and reduce reliance on high‑potency THC products. (CBC)

🗓️ Continued Cannabis News & Events

• The 9 States That Still Haven’t Legalized Medical Cannabis as of July 2026

• The latest science on cannabis has some good news and bad news

• When Recovery Becomes the New Normal After Cannabis and Alcohol

• Kentucky policymakers sound receptive to movement ensuring end-of-life medical cannabis access